Patients with secondary rectal cancer (SRC) after radiotherapy (RT ... less likely to have received total neoadjuvant therapy (52% versus 94%, p < 0.001) Differences in available treatment options.

PD-1 immunotherapy can eliminate the need for surgery in patients with early-stage, DNA mismatch repair-deficient solid cancers, according to results presented by Andrea Cercek, MD, at the AACR Annual ...

You might have total neoadjuvant therapy (TNT). This is chemoradiotherapy or radiotherapy and a course of chemotherapy all before surgery. You might have chemoradiotherapy before surgery if: your ...

Neoadjuvant immunotherapy alone resulted in significant treatment response among most patients with mismatch-repair-deficient ...

"Neoadjuvant therapy” refers to supplemental cancer ... For example, if you have stage 2 or stage 3 colorectal cancer (colon or rectal cancer) and specific factors that make your cancer high ...

Dostarlimab may eliminate the need for surgery in certain patients with dMMR solid tumor malignancies, a phase 2 study suggests.

Neoadjuvant PD-1 blockade in early-stage mismatch repair–deficient solid rectal and non-rectal tumors can eliminate the need ...

We conducted a phase II study to assess the efficacy of combined epirubicin and paclitaxel as neoadjuvant therapy in women with locally advanced or high tumour-to-breast ratio breast cancer to ...